The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2019

Filed:

Nov. 27, 2017
Applicants:

Canon Medical Systems Usa, Inc., Tustin, CA (US);

Board of Regents of the University of Texas System, Austin, TX (US);

Inventors:

Eugene A. Mensah, Tustin, CA (US);

Cecelia Brewington, Plano, TX (US);

Erin Angel, Redondo Beach, CA (US);

Gary Arbique, Desoto, TX (US);

Shaun Nordeck, Sachse, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 6/00 (2006.01); A61B 6/03 (2006.01); G06K 9/62 (2006.01); G06T 7/00 (2017.01); G06K 9/20 (2006.01);
U.S. Cl.
CPC ...
A61B 6/5217 (2013.01); A61B 6/032 (2013.01); A61B 6/4435 (2013.01); A61B 6/504 (2013.01); G06K 9/2054 (2013.01); G06K 9/6268 (2013.01); G06T 7/0014 (2013.01); G06T 2207/10081 (2013.01); G06T 2207/20076 (2013.01); G06T 2207/30064 (2013.01); G06T 2207/30096 (2013.01); G06T 2207/30104 (2013.01);
Abstract

Computed tomography perfusion (CTP) is used in a method to identify cancerous lesions having genetic mutations and treat them accordingly. Also, CTP values are used to distinguish primary versus metastatic lesions. For example, pulmonary blood flow is identified as one biomarker for EGFR and KRAS genetic mutations in lung cancer, lesion having dual-input pulmonary blood flow exceeding a threshold (e.g., 103 ml/min/100 mL with sensitivity 100% and specificity 62%) are determined as having mutations. The CTP values are calculated using a lesion region-of-interest (ROI) placed to include the area of maximum perfusion intensity within the lesion base and surrounding blush, while avoiding regions of perfusion inhomogeneity (e.g., due to necrosis). In certain implementations, instead of a binary determination, the method can generate probabilities associated with respective alternatives (e.g., mutation/non-nutation and/or primary/secondary), and the method can use multivariable statistical analysis that incorporates patient and/or medical information in addition to CTP values.


Find Patent Forward Citations

Loading…